This report was first published by Endpoints News. To see the original version, click here
Pfizer was a late arrival to the obesity gold rush, but it just hit its first seam.
The GLP-1 shot, licensed from Hangzhou-based drugmaker Sciwind Biosciences just a little over a week ago, was approved in China for weight management, Sciwind said Friday, making it Pfizer’s first approved obesity medicine.
您已阅读13%（396字），剩余87%（2570字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。